However, LOF genetic variants became the prototype for the creation of a generation of targeted PCSK9 therapy drugs, which showed unprecedented efficacy in treating dyslipidemia both in CAD and in CAD with T2DM (13, 14). Here, PCSK9 is linked to type 2 diabetes mellitus.